TherapeuticsMD, Inc. (TXMD) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 724K | 893K | 784K | 952K | 393K | 667K | 547K | 234K | 313K | 502K | -53K | 437K |
| Revenue Growth % | 84.22% | 33.88% | 43.33% | 306.84% | 25.56% | 32.87% | 1132.08% | -46.45% | -24.76% | -56.42% | -100.25% | -98.47% |
| Cost of Goods Sold | 325K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 637K | 0 | 0 |
| COGS % of Revenue | 44.89% | - | - | - | - | - | - | - | - | 126.89% | - | - |
| Gross Profit | 399K | 893K | 784K | 952K | 393K | 667K | 547K | 234K | 313K | -135K | -53K | 437K |
| Gross Margin % | 55.11% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | -26.89% | 100% | 100% |
| Gross Profit Growth % | 1.53% | 33.88% | 43.33% | 306.84% | 25.56% | 594.07% | 1132.08% | -46.45% | -24.76% | 94.08% | -100.31% | -98.17% |
| Operating Expenses | 1.12M | 2.39M | 1.61M | 1.65M | 1.26M | 986K | 1.41M | 3.02M | 1.46M | 1.48M | 1.72M | 2.91M |
| OpEx % of Revenue | 154.97% | 267.53% | 205.87% | 173% | 321.63% | 147.83% | 257.04% | 1291.88% | 464.86% | 294.02% | -3245.28% | 665.68% |
| Selling, General & Admin | 1.35M | 2.29M | 1.52M | 0 | 0 | 0 | 0 | 0 | 0 | 1.48M | 1.59M | 2.78M |
| SG&A % of Revenue | 186.88% | 256.66% | 193.62% | - | - | - | - | - | - | 294.02% | -3000% | 636.38% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -231K | 97K | 96K | 1000K | 1000K | 986K | 1000K | 1000K | 1000K | 0 | 130K | 128K |
| Operating Income | -723K | -1.5M | -830K | -695K | -871K | -319K | -859K | -2.79M | -1.14M | -1.61M | -1.77M | -2.47M |
| Operating Margin % | -99.86% | -167.53% | -105.87% | -73% | -221.63% | -47.83% | -157.04% | -1191.88% | -364.86% | -320.92% | 3345.28% | -565.68% |
| Operating Income Growth % | 16.99% | -368.97% | 3.38% | 75.08% | 23.73% | 80.2% | 51.55% | -12.82% | 57.18% | -101.44% | 91.45% | 86.88% |
| EBITDA | -398K | -590K | -734K | -599K | -776K | -219K | -763K | -2.61M | -1.01M | -974K | -1.64M | -2.34M |
| EBITDA Margin % | -54.97% | -66.07% | -93.62% | -62.92% | -197.46% | -32.83% | -139.49% | -1114.96% | -322.36% | -194.02% | 3101.89% | -536.16% |
| EBITDA Growth % | 48.71% | -169.41% | 3.8% | 77.04% | 23.09% | 77.52% | 53.59% | -11.35% | 61.78% | -100.89% | 91.66% | 86.83% |
| D&A (Non-Cash Add-back) | 325K | 906K | 96K | 96K | 95K | 100K | 96K | 180K | 133K | 637K | 129K | 129K |
| EBIT | -723K | -4.15M | 53K | -319K | -783K | -312K | -859K | -1.18M | -1.14M | -1.5M | -1.41M | -2.37M |
| Net Interest Income | 0 | 0 | -3K | -2K | -2K | 0 | -3K | -5K | 0 | 215K | -20K | -45K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 300K | 0 | 0 |
| Interest Expense | 0 | 0 | 3K | 2K | 2K | 0 | 3K | 5K | 0 | 85K | 20K | 45K |
| Other Income/Expense | 826K | 916K | 880K | 1.24M | 203K | 402K | 292K | 1.74M | 333K | 27K | 339K | 58K |
| Pretax Income | 103K | -580K | 50K | 545K | -668K | 83K | -567K | -1.05M | -809K | -1.58M | -1.43M | -2.41M |
| Pretax Margin % | 14.23% | -64.95% | 6.38% | 57.25% | -169.97% | 12.44% | -103.66% | -448.72% | -258.47% | -315.54% | 2705.66% | -552.4% |
| Income Tax | 0 | 32K | 0 | 0 | -32K | -31K | 0 | 0 | 0 | -43K | 0 | 0 |
| Effective Tax Rate % | 0% | -5.52% | 0% | 0% | 4.79% | -37.35% | 0% | 0% | 0% | 2.71% | 0% | 0% |
| Net Income | 95K | -619K | 152K | 551K | -653K | 252K | -609K | -1.09M | -734K | -883K | -3.38M | -2.41M |
| Net Margin % | 13.12% | -69.32% | 19.39% | 57.88% | -166.16% | 37.78% | -111.33% | -465.81% | -234.5% | -175.9% | 6373.58% | -552.4% |
| Net Income Growth % | 114.55% | -345.63% | 124.96% | 150.55% | 11.04% | 128.54% | 81.97% | 54.85% | 79.63% | 97.34% | 88.34% | -102.15% |
| Net Income (Continuing) | 103K | -612K | 50K | 545K | -636K | 114K | -567K | -1.05M | -809K | -1.54M | -1.43M | -2.41M |
| Discontinued Operations | -8K | -7K | 102K | 6K | -17K | 138K | -42K | -40K | 75K | 658K | -1000K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.01 | -0.05 | 0.01 | 0.05 | -0.06 | 0.02 | -0.05 | -0.09 | -0.06 | -0.08 | -0.32 | -0.24 |
| EPS Growth % | 114.51% | -344.29% | 124.81% | 150.37% | 11.16% | 128.59% | 83.5% | 60.62% | 82.81% | 97.84% | 89.78% | -101.94% |
| EPS (Basic) | 0.01 | -0.05 | 0.01 | 0.05 | -0.06 | 0.02 | -0.05 | -0.09 | -0.06 | -0.08 | -0.32 | -0.24 |
| Diluted Shares Outstanding | 11.64M | 11.57M | 11.57M | 11.57M | 11.55M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 10.7M | 10.22M |
| Basic Shares Outstanding | 11.57M | 11.57M | 11.57M | 11.57M | 11.55M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 10.7M | 10.22M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |